Literature DB >> 25657357

Prefrontal glucose metabolism in medication-resistant major depression.

Cheng-Ta Li1, Tung-Ping Su1, Shyh-Jen Wang1, Pei-Chi Tu1, Jen-Chuen Hsieh1.   

Abstract

BACKGROUND: Medication-resistant depression (MRD) is associated with poorer attentional performance and immense socioeconomic costs. AIMS: We aimed to investigate the central pathophysiology of MRD, previously linked to impaired prefrontal cortex function.
METHOD: A total of 54 participants (22 with MRD, 16 with non-resistant depression, 16 healthy controls) were recruited. Non-MRD status was confirmed by a prospective 6-week antidepressant trial. All medication-free participants underwent a go/no-go task to study prefrontal cortical function (attention) and positron emission tomography scans to study regional cerebral glucose metabolism (rCMglu) at rest.
RESULTS: The MRD group had worse attentional ratings and decreased rCMglu compared with the non-MRD and control groups. Attentional performance was positively associated with prefrontal cortex rCMglu. The prefrontal cortex differences between MRD and non-MRD groups remained after adjusting for past depressive episodes (F(1,35) = 4.154, P = 0.043).
CONCLUSIONS: Pronounced hypofrontality, with the associated attentional deficits, has a key role in the neuropathology of medication-resistant depression. Royal College of Psychiatrists.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25657357     DOI: 10.1192/bjp.bp.113.140434

Source DB:  PubMed          Journal:  Br J Psychiatry        ISSN: 0007-1250            Impact factor:   9.319


  16 in total

1.  Altered Long- and Short-Range Functional Connectivity Density in Patients With Thyroid-Associated Ophthalmopathy: A Resting-State fMRI Study.

Authors:  Wen-Hao Jiang; Huan-Huan Chen; Wen Chen; Qian Wu; Lu Chen; Jiang Zhou; Xiao-Quan Xu; Hao Hu; Fei-Yun Wu
Journal:  Front Neurol       Date:  2022-06-23       Impact factor: 4.086

2.  The effects of low-dose ketamine on the prefrontal cortex and amygdala in treatment-resistant depression: A randomized controlled study.

Authors:  Cheng-Ta Li; Mu-Hong Chen; Wei-Chen Lin; Chen-Jee Hong; Bang-Hung Yang; Ren-Shyan Liu; Pei-Chi Tu; Tung-Ping Su
Journal:  Hum Brain Mapp       Date:  2016-01-29       Impact factor: 5.038

3.  Predictive markers of depression in hypertension.

Authors:  Xiuli Song; Zhong Zhang; Rui Zhang; Miye Wang; Dongtao Lin; Tao Li; Junming Shao; Xiaohong Ma
Journal:  Medicine (Baltimore)       Date:  2018-08       Impact factor: 1.889

4.  Abnormal white matter integrity in Chinese young adults with first-episode medication-free anxious depression: a possible neurological biomarker of subtype major depressive disorder.

Authors:  Weiping Xia; Rubai Zhou; Guoqing Zhao; Fan Wang; Ruizhi Mao; Daihui Peng; Tao Yang; Zuowei Wang; Jun Chen; Yiru Fang
Journal:  Neuropsychiatr Dis Treat       Date:  2018-08-10       Impact factor: 2.570

Review 5.  Glutamatergic Dysfunction and Glutamatergic Compounds for Major Psychiatric Disorders: Evidence From Clinical Neuroimaging Studies.

Authors:  Cheng-Ta Li; Kai-Chun Yang; Wei-Chen Lin
Journal:  Front Psychiatry       Date:  2019-01-24       Impact factor: 4.157

6.  A preliminary study of resting brain metabolism in treatment-resistant depression before and after treatment with olanzapine-fluoxetine combination.

Authors:  José V Pardo; Sohail A Sheikh; Graeme Schwindt; Joel T Lee; David E Adson; Barry Rittberg; Faruk S Abuzzahab
Journal:  PLoS One       Date:  2020-01-13       Impact factor: 3.240

7.  Personalization of Repetitive Transcranial Magnetic Stimulation for the Treatment of Major Depressive Disorder According to the Existing Psychiatric Comorbidity.

Authors:  Po-Han Chou; Yen-Feng Lin; Ming-Kuei Lu; Hsin-An Chang; Che-Sheng Chu; Wei Hung Chang; Taishiro Kishimoto; Alexander T Sack; Kuan-Pin Su
Journal:  Clin Psychopharmacol Neurosci       Date:  2021-05-31       Impact factor: 2.582

8.  Magnetic seizure therapy for treatment-resistant depression.

Authors:  Jiangling Jiang; Caidi Zhang; Chunbo Li; Zhimin Chen; Xinyi Cao; Hongyan Wang; Wei Li; Jijun Wang
Journal:  Cochrane Database Syst Rev       Date:  2021-06-16

Review 9.  Unexplained Painful Physical Symptoms in Patients with Major Depressive Disorder: Prevalence, Pathophysiology and Management.

Authors:  Jan Jaracz; Karolina Gattner; Krystyna Jaracz; Krystyna Górna
Journal:  CNS Drugs       Date:  2016-04       Impact factor: 5.749

10.  Modulation of inhibitory control networks relate to clinical response following ketamine therapy in major depression.

Authors:  Ashish K Sahib; Joana Ra Loureiro; Megha M Vasavada; Antoni Kubicki; Benjamin Wade; Shantanu H Joshi; Roger P Woods; Eliza Congdon; Randall Espinoza; Katherine L Narr
Journal:  Transl Psychiatry       Date:  2020-07-30       Impact factor: 7.989

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.